PTC Therapeutics, Inc. (NASDAQ:PTCT)‘s stock had its “neutral” rating reissued by equities researchers at J P Morgan Chase & Co in a research report issued on Tuesday.

A number of other research firms have also recently commented on PTCT. Citigroup Inc. reissued a “buy” rating and issued a $17.00 target price (down previously from $28.00) on shares of PTC Therapeutics in a report on Thursday, July 20th. Barclays PLC reiterated a “hold” rating and issued a $22.00 price objective on shares of PTC Therapeutics in a report on Friday, September 8th. Zacks Investment Research lowered shares of PTC Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, July 1st. BidaskClub lowered shares of PTC Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, August 17th. Finally, William Blair assumed coverage on shares of PTC Therapeutics in a report on Wednesday, August 23rd. They issued a “market perform” rating and a $17.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating and three have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus target price of $17.10.

Shares of PTC Therapeutics (NASDAQ PTCT) traded down 13.84% during midday trading on Tuesday, hitting $16.81. 9,091,238 shares of the stock traded hands. The company’s market capitalization is $694.32 million. PTC Therapeutics has a 52 week low of $4.03 and a 52 week high of $22.00. The firm’s 50-day moving average is $19.53 and its 200 day moving average is $15.36.

PTC Therapeutics (NASDAQ:PTCT) last posted its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.44) EPS for the quarter, topping analysts’ consensus estimates of ($0.89) by $0.45. The firm had revenue of $47.96 million during the quarter, compared to analysts’ expectations of $28.78 million. PTC Therapeutics had a negative net margin of 88.43% and a negative return on equity of 81.84%. The business’s revenue for the quarter was up 206.9% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($1.14) earnings per share. Equities analysts forecast that PTC Therapeutics will post ($2.35) earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: “PTC Therapeutics, Inc. (PTCT) Earns Neutral Rating from J P Morgan Chase & Co” was posted by American Banking News and is the property of of American Banking News. If you are reading this article on another domain, it was illegally copied and republished in violation of U.S. & international copyright laws. The legal version of this article can be accessed at https://www.americanbankingnews.com/2017/09/26/ptc-therapeutics-inc-ptct-earns-neutral-rating-from-j-p-morgan-chase-co.html.

A number of institutional investors have recently added to or reduced their stakes in PTCT. AXA bought a new position in PTC Therapeutics during the 1st quarter worth approximately $103,000. Nisa Investment Advisors LLC bought a new position in PTC Therapeutics during the 2nd quarter worth approximately $125,000. Public Employees Retirement System of Ohio bought a new position in PTC Therapeutics during the 2nd quarter worth approximately $142,000. Virginia Retirement Systems ET AL bought a new position in PTC Therapeutics during the 1st quarter worth approximately $187,000. Finally, Prudential Financial Inc. bought a new position in PTC Therapeutics during the 2nd quarter worth approximately $201,000. Hedge funds and other institutional investors own 81.30% of the company’s stock.

PTC Therapeutics Company Profile

PTC Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of medicines using its expertise in ribonucleic acid (RNA) biology. Its product pipeline includes Ataluren (Translarna), PTC596 and RG7916. Its product candidate, ataluren, is an orally administered small-molecule compound for the treatment of patients with genetic disorders due to a nonsense mutation.

Analyst Recommendations for PTC Therapeutics (NASDAQ:PTCT)

Receive News & Ratings for PTC Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PTC Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.